Incorrect headline could be cause of Selecta weakness, says Cantor Fitzgerald » 16:0207/2207/22/21
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Kristen Kluska notes that Seleta Biosciences (SELB) shares have been trading down on Thursday, despite the company not reporting any news-related items. The analyst thinks shares are trading down as a result of a Bloomberg article highlighting the setback reported in the microbiome space from Seres (MCRB). Kluska says "the article incorrectly lists Selecta Biosciences as a related ticker." as Selecta is "not a microbiome-based company." Overall, the analyst sees "no fundamental reasons" for the weakness in the shares and reiterates an Overweight rating and a price target of $9 on the stock.
|Over a week ago|
Selecta Biosciences appoints Nishan de Silva to board of directors » 08:1806/2406/24/21
Selecta Biosciences announced the appointment of Nishan de Silva, M.D. to its Board of Directors. Dr. de Silva will provide strategic guidance and operational insights as Selecta continues to advance its clinical pipeline. Dr. de Silva is currently Chief Executive Officer and Director of AFYX Therapeutics.
|Over a month ago|
Selecta Biosciences initiated with a Buy at BTIG » 16:3606/1406/14/21
BTIG analyst Yun Zhong…
BTIG analyst Yun Zhong initiated coverage of Selecta Biosciences with a Buy rating and $10 price target. The analyst sees significant potential in the company's ImmTOR technology platform beyond the chronic refractory gout program. Zhong added that he believes SEL-212's clinical data to date have demonstrated "strong" efficacy and safety to support an FDA approval.
Selecta announcer paper on hepatic tolerogenic potential of ImmTOR » 08:0906/0106/01/21
Selecta Biosciences announced the peer-reviewed publication of a study investigating the effects of ImmTOR nanoparticles in generating a tolerogenic environment in the liver. The data, published in a Frontiers in Immunology paper titled "Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles," demonstrate that ImmTOR induces a tolerogenic phenotype in all major resident antigen-presenting cell populations in the liver, resulting in modulation of hepatic T cell populations. These findings demonstrate the capability of Selecta's ImmTOR platform in promoting hepatic immune tolerance, providing support for the potential of ImmTOR for the treatment of autoimmune diseases affecting the liver. "Liver specific autoimmune diseases result from the loss of natural immunological tolerance to hepatic autoantigens," said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. "The data outlined in this publication demonstrate that ImmTOR could effectively enhances the tolerogenic environment of the liver by inducing tolerogenic antigen-presenting cells and was observed to be protective in an acute mouse model of autoimmune hepatitis. These data are of particular relevance to our primary biliary cholangitis program, and we look forward to building on these findings as we advance our first autoimmune program towards the clinic."
Selecta Biosciences expects cash to fund requirements into 2Q23 » 08:0605/1305/13/21
Selecta had $149.2…
Selecta had $149.2 million in cash, cash equivalents, marketable securities, and restricted cash as of March 31, 2021, which compares to cash, cash equivalents, and restricted cash of $140.1 million as of December 31, 2020. Selecta believes its available cash, cash equivalents, marketable securities, and restricted cash will be sufficient to meet its operating requirements into the second quarter of 2023.
Selecta Biosciences reports Q1 EPS (22c), consensus (12c) » 08:0605/1305/13/21
Reports Q1 revenue…
Reports Q1 revenue $11.1M, consensus $7.52M. "We are very pleased about the continued progress across all aspects of the company," said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. "We regained exclusive rights to our MMA program and now have two proprietary gene therapy programs to rapidly follow our ongoing empty capsid study. Additionally, we continue to progress our enzyme program, with an expected IND filing by the end of 2021 in IgA nephropathy, and topline data from the Phase 3 DISSOLVE program for SEL-212 anticipated in the second half of 2022."
Mizuho sees 'minimal impact' to Selecta Biosciences from AskBio assumption news » 13:3704/2904/29/21
After Selecta Biosciences…
After Selecta Biosciences and Asklepios BioPharmaceutical announced that Selecta will assume all rights to the companies' collaboration to evaluate gene therapy candidate MMA-101 and ImmTOR for the treatment of methylmalonic acidemia, Mizuho analyst Difei Yang said she sees "minimal impact" from the news and views it as "immaterial" to Selecta's valuation. Noting that MMA was the sole metabolic disease in AskBio's pipeline, Yang said she is not surprised that the company has decided to exit the indication following a strategic review. Yang has a Buy rating and $8 price target on Selecta shares.
Selecta Biosciences assume all rights to MMA program from AskBio » 08:3704/2904/29/21
Selecta Biosciences and…
Selecta Biosciences and Asklepios BioPharmaceutical announced an update to the companies' collaboration to evaluate gene therapy candidate MMA-101 and ImmTOR for the treatment of methylmalonic acidemia. Selecta will assume all rights to the MMA program and will continue to progress the MMA-101 and ImmTOR combination through clinical development. AskBio's decision to give all rights to Selecta is based on an internal strategic review and prioritization of its portfolio. Due to a manufacturing issue the company believes is related to a component sourced from a third-party, Selecta now expects that submission of the IND for MMA-101 and ImmTOR will be delayed until at least the fourth quarter of 2021. A detailed assessment of the manufacturing process is currently being conducted, and the Company expects to provide an update on program timelines as they are clarified. ImmTOR manufacturing continues to proceed smoothly, and there is no impact to any of Selecta's ImmTOR programs. The dose-escalation trial of SEL-399, an adeno-associated viral serotype 8 empty vector capsid containing no DNA combined with ImmTOR, is currently underway and progressing as expected. The study, being conducted in healthy volunteers at the SGS Life Sciences Clinical Pharmacology Unit in Antwerp, Belgium, is designed to evaluate the safety and preliminary efficacy of ImmTOR in gene therapy. Selecta and AskBio intend to provide topline data in the fourth quarter of this year.
|Over a quarter ago|
Selecta Biosciences Chief Medical Officer buys 20K shares of common stock » 17:5703/1903/19/21
In a regulatory filing,…
In a regulatory filing, Selecta Biosciences disclosed that its Chief Medical Officer Peter Traber bought 20K shares of common stock in a total transaction size of $90K, boosting his stake by about 26%.
Selecta upgraded to Outperform ahead of catalysts at William Blair » 07:0903/1203/12/21
William Blair analyst…
William Blair analyst Raju Prasad upgraded Selecta Biosciences to Outperform from Market Perform without a price target. The analyst believes data from Selecta's Phase I study of SEL-399, anticipated in Q4, has potential to drive "significant value." After a deep dive into the ImmTOR published literature to date, Prasad views Selecta's non-human primates data favorably and as supporting a positive risk/reward ratio going into the upcoming Phase I trial and future gene therapy studies with ImmTOR. Between now and 2022 the analyst sees "several catalysts that can drive the stock significantly."